Patent ID: 11918586
Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of preventing or treating a skin lesion in a subject in need thereof, wherein said skin lesion is a non-melanoma skin cancer, and wherein said non-melanoma skin cancer is selected from basal cell carcinoma and actinic keratosis; said method comprising administering an effective amount of a compound of formula (I) to said subject,, wherein
X1, X2 and X3 are N;
Y is N or CH;
W is F;
R1 and R2 are independently of each other
(i) a morpholinyl of formula (II), wherein the arrow denotes the bond in formula (I); and
wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structures, wherein the arrows denote the bonds in formula (II); or
(ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl; or two R7 substituents form together a bivalent residue —R8R9— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2— or —O—CH2CH2—O—;

with the proviso that at least one of R1 and R2 is a morpholinyl of formula (II);
and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof.